Global Study on Peptic Ulcer Drugs Market, 2016 - 2022

<strong>Global</strong> <strong>Study</strong> on Peptic Ulcer Drugs Market, 2016 - 2022
Persistence Market Research
<strong>Global</strong> Peptic Ulcer Drugs Market to Reach
US$ 40.0 Bn by 2022: Persistence Market
Research
Persistence Market Research 1

<strong>Global</strong> <strong>Study</strong> on Peptic Ulcer Drugs Market, 2016 - 2022
Persistence Market Research Released New Market Report According to a new market report
published by Persistence Market Research ‘<strong>Global</strong> Market <strong>Study</strong> on Peptic Ulcer Drugs:
North America to Lead in <strong>Global</strong> Market During Forecast Period 2016 - 2022,
Driven by Increasing NSAID Consumption ’. According to this report, the global peptic
ulcer drugs market will expand at CAGR of 2.8% during the forecast period 2016-2022.
The market is segmented on the basis of product type, disease indication, distribution
channel and region. By product type, the global peptic ulcer drugs market has been
segmented into proton pump inhibitor (PPI), potassium-competitive acid blockers (P-CAB),
antacids, H2-antagonists, antibiotics, and ulcer protective. Proton pump inhibitor segment
was the largest revenue generating segment, contributing 69.1% share to the overall
revenue of the global peptic ulcer drugs market in 2014. Revenue from the potassiumcompetitive
acid blockers segment is expected to expand rapidly at a CAGR of 4.5% owing
to introduction of new P-CAB drugs in the market. Based on indication, the global market for
peptic ulcer drug is segmented as gastritis, gastric ulcers, duodenal ulcers, and
gastroesophageal reflux disease. Gastric ulcer segment is anticipated to expand at highest
CAGR of 3.0% over the forecast period.
On the basis of distribution channels, the global peptic ulcer drugs market has been
segmented as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-
Commerce. Among these, hospital pharmacies segment led the global market for peptic
ulcer drugs in 2014 and is expected to remain the leading segment. Increasing
hospitalization rates due to ulcer complications is expected to be the primary factor fuelling
revenue growth of the hospital distribution channel segment over the forecast period.
Geographically, peptic ulcer drugs market is segmented into five key regions: North
America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Surge in consumption of NSAIDs due to growing prevalence of inflammatory diseases is the
major factor driving growth of the global peptic ulcer drugs market. Other trends driving
growth include increasing adoption of peptic ulcer drugs over surgery, changes in disease
management, prevalence of stress ulcers due to higher smoking rates, availability of
affordable therapy due to improvement in service sector, increasing awareness toward
disease management through government campaigns etc. Chronic side effects associated
Persistence Market Research 2

<strong>Global</strong> <strong>Study</strong> on Peptic Ulcer Drugs Market, 2016 - 2022
with long term use of peptic ulcer drugs is the major factor hampering the growth of global
peptic ulcer drugs market.
This report assesses trends driving each segment and offers analysis and insights about the
potential of peptic ulcer drugs in specific regions. North America is expected to dominate the
market, with a maximum share by the end of 2015. North America and Europe collectively
accounted for 67% share of global peptic ulcer drugs market in 2014. Asia Pacific is
estimated to be the fastest growing market, registering a CAGR of 3.5% during the forecast
period.
The report begins with overview of peptic ulcer drugs market in terms of value. This section
covers optimistic, likely and conservative scenario in peptic ulcer drugs market. Overview of
product launches in the peptic ulcer drugs market explains the evolution of treatment
options over time. This report offers analysis of drivers, restraints, key trends in the region
and global market, and potential opportunities to provide a client with clear insights to make
better and informed decisions.
Request Sample Report: http://www.persistencemarketresearch.com/samples/3704
Key players operating in this market are Daewoong Pharmaceutical Co. Ltd., Takeda
Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca Plc., Cadila
Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and
GlaxoSmithKline Pharmaceuticals Ltd. These companies are primarily focusing on strategies
such as co-promotions and co-marketing of their brands to penetrate the fastest growing
emerging markets.
View Detail Report With TOC: http://www.persistencemarketresearch.com/marketresearch/peptic-ulcer-drugs-market.asp
Market History:
Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric
ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD). Drugs used for the
treatment of peptic ulcer include those which reduce gastric ulcer secretion such as PPI and
H2 receptor antagonists, acid neutralization agents such as antacids and antibiotics against
H. pylori infection. However, these drugs are often used in combination for effective
Persistence Market Research 3

<strong>Global</strong> <strong>Study</strong> on Peptic Ulcer Drugs Market, 2016 - 2022
treatment. Depending upon the product type, peptic ulcer drugs market is segmented into
proton pump inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), antacids, H2
antagonists, antibiotics, and ulcer protective drugs. On the basis of indications, the market
has been segmented into gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal
reflux disease (GERD). By distribution channel, the global peptic ulcer drugs market is
segmented into hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-
Commerce.
The global peptic ulcer drugs treatment market was valued at US$ 32,200 Mn in 2014. North
America led the global market 2014, accounting for 41.2% share of total global market
revenue. The surge in use of non-steroidal anti-inflammatory drugs (NSAID) such as aspirin
and growing awareness regarding treatment options for peptic ulcers are factors expected to
drive the growth of the peptic ulcer drugs market in North America. The market in Europe
accounted for a second largest share of 25.8%, primarily due to easy availability of
successful treatment options for peptic ulcers in the region.
Revenue from the global peptic ulcer drugs market is projected to expand at a steady CAGR
of 2.8% over the forecast period and is expected to be valued at US$ 40,004.3 Mn by 2022
end. North America is expected to remain the dominant market, contributing 41.5% share to
the global peptic ulcer drugs market in terms of revenue. The PPI and H2 antagonist product
segments collectively accounted for 79.2% revenue share in 2014. The gastric ulcer
indication segment was valued at US$ 5,279.8 Mn in 2014 and is expected to register the
highest CAGR of 3.0% over the forecast period.
Factors driving the growth of the global peptic ulcer drugs market include growing
prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D
stimulation through government policies, increasing a number of generic manufacturers of
peptic ulcer drugs, changes in disease management etc. Furthermore, factors such as
growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing
smoking rate, and progressive population of geriatrics are anticipated to promote the growth
of the global peptic ulcer drugs market over the forecast period. However, side effects of
peptic ulcer drugs, poor pipeline productivity, and changes in pricing policies of drugs are
factors expected to hamper the growth of the global peptic ulcer drugs market during this
period.
Persistence Market Research 4

<strong>Global</strong> <strong>Study</strong> on Peptic Ulcer Drugs Market, 2016 - 2022
Top players in the global peptic ulcer drugs market covered in this report are Daewoong
Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott
Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai
Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Plc.
Follow us on Linkedin: https://www.linkedin.com/company/persistence-market-research-&-
consulting
About Us:
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated
research, custom research, and consulting services. PMR boasts market research expertise across the
Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages,
Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The
company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data
that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research 5

<strong>Global</strong> <strong>Study</strong> on Peptic Ulcer Drugs Market, 2016 - 2022
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
Persistence Market Research 6